NCT00171756CompletedPhase 4
A Double-blind, Double-dummy, Multi-centre, Randomized, Active Controlled, Parallel Group Pilot Trial to Compare the Effects of Valsartan and Atenolol on the Pro-thrombotic State in Patients With Mild to Moderate Hypertension.
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Change from baseline in a clinical laboratory measurement of a blood clotting factor after 12 weeks
Study Overview
Brief Summary
A study to compare the effects of Diovan or Atenolol taken for 12 weeks on platelet function of patients who have mild to moderately severe hypertension
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, aged between 18 - 75 years of age inclusively.
- •Mild to moderate hypertension (MSDBP >= 95 and >= 110 mmHg and / or MSSBP >140mm Hg) at visit 1, requiring pharmacological intervention. For newly diagnosed patients, hypertensive blood pressure values must be noted on at least two successive examinations prior to entry into the study. In addition, patients must require therapy despite having been following dietary & lifestyle advice for at least 3 months.
- •Written informed consent to participate in the study, prior to any study procedures.
- •Ability to communicate and comply with all study requirements
Exclusion Criteria
- •o Uncontrolled hypertension defined as seated blood pressure of either systolic BP >180 mmHg and/or diastolic BP >110mmHg.
- •Clinically significant laboratory abnormalities that may interfere with the assessment of safety and/or efficacy of the study drug
- •Patients with severe medical condition(s) that in the view of the investigator may prohibit participation in the study
- •Renal artery stenosis
- •Diabetes Mellitus
- •Any condition resulting from or leading to platelet or clotting abnormalities (eg. hemophilia, von Willebrand's disease).
- •History of a vascular event or intervention (e.g. MI, PTCA or CABG) within 6 months preceding the study.
- •History of clinically significant angina, LVH, transient ischemic attack, stroke, intermittent claudication, deep vein thrombosis (DVT), pulmonary embolism or peripheral vascular disease.
- •Uncontrolled atrial fibrillation (>100 b.p.m. at rest) or other conditions which may require anti-aggregant or anti-vitamin K therapies.
- •Clinical evidence of congestive heart failure.
- •Evidence of second or third degree heart block or sick sinus syndrome.
Outcomes
Primary Outcomes
Change from baseline in a clinical laboratory measurement of a blood clotting factor after 12 weeks
Secondary Outcomes
- Change from baseline in clinical laboratory measurements of blood clotting factors, including platelet activation, thrombosis, fibrinolysis, anticoagulation after 12 weeks
- Blood pressure of 140/85 mmHg or lower after 12 weeks
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or PrasugrelCoronary Artery DiseaseNCT05247385University of Sao Paulo87
Recruiting
Not Applicable
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized TrialElevated Lipoprotein(a) LevelDrug-Eluting StentDual Antiplatelet TherapyCoronary Artery DiseaseNCT06014060China National Center for Cardiovascular Diseases3,300
Recruiting
Phase 3
SAPT Versus DAPT in Incomplete Revascularization After CABGCoronary Artery DiseaseNCT03789916Campus Bio-Medico University800
Completed
Phase 4
Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction ProcessAplasia With Expected ThrombocytopeniaNCT01789762Etablissement Français du Sang842
Completed
Phase 4
Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMIMyocardial InfarctionCardiovascular DiseaseNCT01459627Maasstad Hospital1,100